Table 1.
Patients demographic characteristics both at baseline and after 12 weeks of treatment.
| All patients (N = 96) | Pre-treatment (n = 77) | Post-treatment (n = 52) | Pre- and post-treatment (n = 33) | |
|---|---|---|---|---|
| Female, n(%) | 79 (82.3) | 63(81.8) | 45(86.5) | 29(87.9) |
| Age (years) | 51.1 ± 14.1 | 51.97 ± 13.78 | 49.88 ± 14.41 | 51.42 ± 13.91 |
| Disease duration (years) | 7.06 ± 7.14 | 7.12 ± 6.84 | 6.25 ± 6.92 | 5.92 ± 6.02 |
| ESR(mm/h) | 51.58 ± 29.47 | 51.27 ± 29.04 | 53.87 ± 29.06 | 56.52 ± 27.72 |
| CRP (mg/L) | 37.36 ± 37.20 | 40.21 ± 39.93 | 34.3 ± 34.76 | 39.18 ± 40.43 |
| T28 | 7.40 ± 6.59 | 7.13 ± 6.28 | 7.13 ± 6.72 | 5.85 ± 4.7 |
| SW28 | 5.36 ± 5.36 | 5.43 ± 5.31 | 4.96 ± 5.32 | 4.42 ± 4.26 |
| PGA | 5.59 ± 1.68 | 5.55 ± 1.63 | 5.63 ± 1.67 | 5.61 ± 1.46 |
| HAQ | 0.87 ± 0.57 | 0.88 ± 0.57 | 0.83 ± 0.55 | 0.76 ± 0.53 |
| SDAI | 60.01 ± 42.99 | 63.63 ± 46.4 | 57.26 ± 38.47 | 21.18 ± 9.71 |
| CDAI | 23.65 ± 13.66 | 23.43 ± 13.3 | 22.96 ± 13.47 | 60.37 ± 44.99 |
| DAS28-CRP | 4.20 ± 1.29 | 4.26 ± 1.3 | 4.08 ± 1.23 | 4.1 ± 1.2 |
| Tacrolimus treatment, n(%) | ||||
| TAC | 1 (1.04) | 1(1.3) | 1(1.9) | 1(3.0) |
| TAC + M | 15 (15.6) | 14(18.2) | 6(11.5) | 5(15.2) |
| TAC + P | 37(38.5) | 26(33.8) | 21(40.4) | 10(30.3) |
| TAC + M + P | 38(39.6) | 31(40.3) | 24(46.1) | 17(51.5) |
| UK | 5 (5.2) | 5(6.5) | - | - |
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, T28: tender joints of 28 counted, SW28: swollen joints of 28 counted, PGA: patient global assessment, HAQ: health assessment questionnaire, SDAI: simplified disease activity index, CDAI: clinical disease activity index, DAS28: disease activity score in 28 joints, TAC: tacrolimus, M: methotrexate, P: prednisone, UK: uncertain drugs combined with tacrolimus. Values are shown as mean ± standard deviation or n (%).